--- title: "TG Therapeutics (TGTX) news: buyback" url: "https://aibio.space/companies/tg-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TGTX buyback news. TG Therapeutics news for investors: TG Therapeutics sells BRIUMVI (ublituximab), an anti-CD20 antibody infusion for relapsing multiple…" --- Desk view · Opinion · Updated Oct 22, 2026 ## TG's BRIUMVI is working. Subcutaneous dosing is the next bet TG has a fast-growing, profitable MS drug and two line extensions that look likely to work. The company has added debt and spent heavily to prepare a subcutaneous version, so the phase 3 readout carries more weight than its low scientific risk suggests. Its early bets outside MS remain speculative. Read the full desk view aibio.space Investor Rank · Opinion **8** /10 Positive view BRIUMVI is profitable with U.S. sales up 64% and line extensions look likely to work, but it is a one-drug company carrying a $750 million term loan. - **Technology**: 2/2 - **Odds**: 2/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven in market.** BRIUMVI's seven-year data show 88.3% of continuously treated patients free of confirmed disability progression, and U.S. sales grew about 64% in Q2. - **Odds**: **Low-risk extensions.** ENHANCE met its bioequivalence endpoint, and modeled exposure for the subcutaneous phase 3 sits well above the non-inferiority bar, though azer-cel is still phase 1. - **Balance sheet**: **Profitable with debt.** TG held $612.3 million in cash and investments at June 30 against a $750 million term loan. - **Main risk**: **One-drug company.** Almost all revenue is BRIUMVI, and heavy subcutaneous manufacturing spending cut Q2 net income to $7.8 million. - **Watch next**: **Subcutaneous phase 3.** Topline data are due at year-end 2026 or in the first quarter of 2027. ## Top news on TG 1. 2026-05-06 Financings [TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million](https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/) First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. ## Dates **Second half of 2026** Preliminary phase 1 azer-cel data in progressive MS; TG announced a late-breaking oral presentation at MSToronto2026 for October 23 [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) **Second half of 2026** Supplemental BLA submission for single-infusion BRIUMVI initiation [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/ex_968837.htm) **Year-end 2026 or first quarter of 2027** Topline phase 3 data for subcutaneous BRIUMVI [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) **2028** Potential approval of subcutaneous BRIUMVI, per TG [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/ex_970980.htm) ## The money $612.3 million in cash, cash equivalents and investment securities at June 30, 2026. TG says this plus projected BRIUMVI revenue will fund its current operating plan. Loan payable was $745.4 million. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) Q2 2026 total global revenue $240.3 million, including BRIUMVI U.S. net product revenue of $227.7 million (up about 64%). 2026 guidance: about $950 million total, $890 million to $905 million U.S. BRIUMVI. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) ## Risks on the record - Nearly all revenue comes from BRIUMVI, and the 10-Q warns of substantial competition and reliance on sole-source third-party suppliers for drug substance and drug product. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) - TG carries a $750 million Blue Owl term loan maturing March 18, 2031. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm) - In MS trials, serious infections occurred in 5% of BRIUMVI patients versus 3% on teriflunomide, with three infection-related deaths on BRIUMVI. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for TG Therapeutics? 8 out of 10, our positive view. BRIUMVI is profitable with U.S. sales up 64% and line extensions look likely to work, but it is a one-drug company carrying a $750 million term loan. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What is BRIUMVI? BRIUMVI (ublituximab-xiiy) is TG Therapeutics' anti-CD20 antibody given by infusion for relapsing forms of multiple sclerosis in adults. It is glycoengineered to deplete B cells at low doses. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) ### What is TG Therapeutics' 2026 revenue guidance? In August 2026 TG raised its full-year targets to about $950 million in total global revenue and $890 million to $905 million in U.S. BRIUMVI net product revenue. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) ### When will subcutaneous BRIUMVI phase 3 data come out? TG expects topline phase 3 data at year-end 2026 or in the first quarter of 2027, and has pointed to a potential approval in 2028. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/ex_970980.htm) ### Is TG Therapeutics profitable? Yes. TG reported net income of $7.8 million in the second quarter of 2026 and $27.6 million for the first half, though profit fell as subcutaneous manufacturing costs rose. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) ### What is azer-cel? Azer-cel is an allogeneic, off-the-shelf CD19-directed CAR-T cell therapy that TG is testing in a phase 1 study in progressive MS and B-cell mediated autoimmune disorders. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) ### What is the latest TG Therapeutics (TGTX) stock news? Our latest story on TG Therapeutics, dated May 6, 2026: "TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million". First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. [Source](https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/) ### What is TG Therapeutics's latest stock offering or financing news? Our latest financing story, dated May 6, 2026: "TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million". First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. [Source](https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/) ### What is TG Therapeutics's market cap? We do not publish live share prices. In its annual report, TG Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $2.50 billion as of Jun 30, 2025. Source ### Is TG Therapeutics a smaller reporting company? SEC records list TG Therapeutics, Inc.'s filer category as: Large accelerated filer. Source ### Where is TG Therapeutics headquartered? SEC records list its business address as 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014. Source ### When does TG Therapeutics's fiscal year end? TG Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did TG Therapeutics last file with the SEC? Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) ### What was TG Therapeutics called before? SEC records list these former names: MANHATTAN PHARMACEUTICALS INC; ATLANTIC TECHNOLOGY VENTURES INC; ATLANTIC PHARMACEUTICALS INC. Source ### What industry is TG Therapeutics in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ## Legal and investor matters Checked against TG Therapeutics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Part II, Item 1 of the 10-Q filed 2026-08-05 states: "We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings." [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) 1. 2026-03-18 Financing TG Therapeutics establishes $750 million term loan with Blue Owl On 2026-03-18 TG Therapeutics amended its financing agreement with Blue Owl Capital Corporation as administrative agent. The amendment set up a $750 million term loan, borrowed in full that day, and part of the proceeds repaid the initial term loans. It also created an uncommitted additional facility of up to $250 million. The 2026 term loan matures on 2031-03-18. [TG Therapeutics Form 8-K (Items 1.01, 2.03)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | BRIUMVI (ublituximab-xiiy), IV | Relapsing multiple sclerosis | Marketed in the U.S.; sold ex-U.S. through Neuraxpharm [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm) | | BRIUMVI single 600 mg initiation infusion (ENHANCE) | Relapsing multiple sclerosis | Phase 3 met primary endpoint; supplemental BLA targeted 2H 2026 [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/ex_968837.htm) | | Subcutaneous ublituximab | Relapsing multiple sclerosis | Phase 3 fully enrolled; topline data year-end 2026 or Q1 2027 [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/ex_970980.htm) | | Azer-cel (allogeneic CD19 CAR-T) | Progressive MS and B-cell mediated autoimmune disorders | Phase 1 [Source](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) | | BRIUMVI | Myasthenia gravis (maintenance after efgartigimod induction) | Phase 2, potentially registration-directed [Source](https://clinicaltrials.gov/study/NCT07673744) | | BRIUMVI | Treatment-resistant schizophrenia | Phase 2 [Source](https://clinicaltrials.gov/study/NCT07680946) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TGTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-TGTX/). ## SEC filings and registration - **SEC name**: Tg Therapeutics, Inc. - **CIK**: 1001316 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TGTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014 - **Phone**: (212) 554-4484 - **Shares outstanding**: 153,069,053 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: MANHATTAN PHARMACEUTICALS INC; ATLANTIC TECHNOLOGY VENTURES INC; ATLANTIC PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/tgtx20260730_8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926020491/tgtx20260612_8k.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/tgtx20260602_8k.htm) filed 2026-06-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015246/tgtx20260331_10q.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/tgtx20260227_8k.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1001316/000143774926014233/tgtx20260301_def14a.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001001316), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tg-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TG Therapeutics (TGTX) news: buyback", 2026-10-31, https://aibio.space/companies/tg-therapeutics/